Abnormal Intracellular Localization of Bax with a Normal Membrane Anchor Domain in Human Lung Cancer Cell Lines

Alaa-eldin Salah-eldin, Shoichi Inoue,1 Masumi Tsuda and Akihiro Matsuura

Department of Environmental Medicine and Informatics, Graduate School of Environmental Earth Science, Hokkaido University, Kita-10 Nishi-5, Kita-ku, Sapporo 060-0810

Proapoptotic Bax is a member of the Bcl-2 family proteins, which have a key role in regulating programmed cell death. The intracellular localization and redistribution of Bax are important in promoting apoptosis. Bax contains a BH3 domain heterodimerizing with Bcl-2 and a hydrophobic transmembrane segment to be inserted in specified organelle membranes. In this study, Bcl-2 showed cytoplasmic localization in all of ten human lung cancer cell lines tested. Interestingly, Bax was localized in the nucleus in 7 cell lines, although Bax lacks nuclear import signals. This may allow cancer cells to escape from apoptosis. Why Bax is able to exist in the nucleus is still unclear. We hypothesized that mutation in the BH3 domain and/or transmembrane segment of Bax possibly causes intracellular Bax distribution. We analyzed the sequence of the bax gene in these cell lines and found only a silent point mutation at codon 184 (TCG → TCA) in the transmembrane segment in all cell lines. This finding indicates that changes in cellular localization of Bax in lung cancer cell lines do not depend on bax mutation and that Bax is possibly translocated into the nucleus without any mutation. This is the first report showing that Bax with the normal amino acid sequence can be localized in the nucleus in established lung cancer cell lines without any treatment of the cells.

Key words: Bax localization — BH3 domain — Transmembrane segment

Of the Bcl-2 family proteins, some members including Bcl-2, Bcl-XL, Bcl-W, Mcl-1 and A1 promote cell survival, while other members including Bax, Bad, Bid, Bak, Bcl-XS, Bik, Bim and HRK potentiate apoptosis.3) This family is specifically defined by four regions that share amino acid sequence homology, designated BH1, BH2, BH3, and BH4.2, 3) Mutational analysis has indicated the importance of BH1 and BH2 for the antiapoptotic function of Bcl-2 and Bcl-XL, as well as the binding to Bax,4) while the BH4 domain is vital for the death-repressor function. The BH3 domains of Bax and Bak are critical for promoting cell death and dimerization with Bcl-2 and Bcl-XL.5, 6) Most Bcl-2 family proteins contain a single predicted transmembrane segment at their extreme carboxylic terminal region, which is presumed to function in anchoring these proteins to organelle membranes.7)

Bax has been suggested to target organelle membranes,8) particularly mitochondria,9) using the C-terminal hydrophobic region. By means of an immuno-histochemical technique and subcellular fractionation,10) Bax has been detected in the cytosol. A recent study showed that Bax requires Bcl-2 to associate with organelle membranes11) and the BH3 domain of Bax is critical for heterodimerization with Bcl-2.4, 5) Alteration in the subcellular distribution of Bax is important, as it suggests that Bax redistribution may have a role in apoptosis.12–15) Most of the previous studies have indicated that Bax translocates to the mitochondria and becomes a membrane-bound form following the induction of apoptosis.10, 12, 16, 17) On the other hand, the nuclear localization of Bax during induction of apoptosis has been reported in many kinds of cells, such as immortalized lung cancer cells during hyperthermia treatment,18) fibroblasts after both γ-irradiation and topotecan treatment,19) some dying neurons in hippocampus and entorhinal cortex after kainic acid administration in the rat,20) and human colorectal carcinoma cells after growth factor deprivation.13) We also found that Bax was localized in the nucleus in seven of ten cell lines without any apoptotic stimulus, although it lacks the nuclear localizing sequence (NLS) in the primary structure.21) Ions and other small molecules passively diffuse through ~10 nm aqueous channels in the nuclear pore complexes. Most macromolecules are too large to pass through these diffusional channels and are transported through a central gated channel in an ATP- and temperature-dependent manner.10) If 21-kDa Bax is distributed through the aqueous channels of 10 nm or less in the nuclear pore complexes, like ions and other small molecules, Bax should exist equivalently in both the cytoplasm and the nucleus, as was observed in one cell line. However, as we found that Bax was localized only in the nucleus in three cell lines, we considered that Bax should be translocated into the nucleus by an active transport mechanism after translation from mRNA in the cytoplasm. The question then arose, does Bax newly acquire NLS due to Bax mutation?

1To whom requests for reprints should be addressed.
E-mail: inoues@ees.hokudai.ac.jp
The bax gene encodes six exons and shows a complex pattern of alternative mRNA splicing. Six different Bax variants have thus far been characterized: 21-kDa Baxα21 and 15.8-kDa Baxβ21 that have a putative transmembrane domain, and 24-kDa Baxδ, 4.5-kDa Baxε, 28-kDa Baxω22 and 18-kDa Baxζ23 that lack the hydrophobic transmembrane segment. In vivo studies suggest that a single protein product predominates for each gene, and Baxα is the predominant transcript in the human lung.21,22,23 Moreover, we detect Bax as a 21-kDa single band by western blotting. Therefore, Bax that we detected in this study should be Baxα.

In this study, we focused on the association of Bax localization with Bax mutation in human lung cancer cell lines. Therefore, we analyzed the sequence of the bax gene in these cell lines to test if the nuclear localization of Bax is a result of bax mutation.

**MATERIALS AND METHODS**

**Cell lines** Ten human lung cancer cell lines used were squamous cell carcinomas (NPC-2, NPC-5, PC-10, and QG-56), adenocarcinomas (PC-3, PC-4, and NPC-8), and small cell carcinomas (NPC-1, PC-6, and QG-90).25 The cells were cultured in RPMI 1640 medium (Gibco, Grand Island, NY) containing 10% fetal bovine serum (Hyclone, Logan, UT) and 7% dexamethasone (Sigma), and 7% human serum (Shuzo, Otsu), 10% fetal bovine serum (Gibco, Grand Island, NY) containing 10% fetal bovine serum (Gibco) (complete medium) in a humidified atmosphere of 5% CO2 at 37°C. The medium was replaced with fresh complete medium every three days.

**Antibodies** The anti-human Bcl-2 mouse monoclonal antibody (Bcl-2 mAb; Oncogene Science, Cambridge, MA) and anti-human Bax rabbit polyclonal antibody (Bax pAb; PharMingen, San Diego, CA) were developed using synthetic peptides corresponding to the amino acid residues 41–54 of human Bcl-2 and 43–61 of human Bax as immunogens, respectively.

**Protein extraction** Cells were harvested by scraping, washed twice with ice-cold phosphate-buffered saline (PBS), and lysed with a lysis buffer [10 mM Tris (pH 7.4), 150 mM NaCl, 1% Triton X-100, 1% Na-deoxycholate (Kanto Chemical, Tokyo), 0.1% sodium dodecyl sulfate (SDS) (Kanto Chemical), 5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM phenylmethylsulfonyl fluoride (Sigma, St. Louis, MO), 0.28 U/ml aprotinin (Takara Shuzo, Otsu), 10 μM leupeptin (Sigma), 1 mM benzamidine (Sigma), and 7 μg/ml pepstatin A (Sigma)] for 30 min then centrifuged at 15 000 rpm for 30 min.

**Western blotting** Western blotting was performed by the method of Krajewski et al.,26 with minor modification. Briefly, samples containing 100 μg protein were subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE, 12% gels). The proteins were transferred to Hybond-P (polyvinylidene difluoride; PVDF membrane, Amersham, Buckinghamshire, UK) membranes, which were blocked overnight at 4°C with 5% non-fat milk in PBS containing 0.1% Tween 20 (TPBS). The membranes were then incubated for 1 h at room temperature with anti-human Bcl-2 mouse mAb (1:200 dilution) or anti-human Bax rabbit pAb (1:1000 dilution). They were washed twice with TPBS, then incubated for 1 h at room temperature with horseradish peroxidase (HRP)-linked anti-mouse immunoglobulin (Ig) (1:300 dilution; Amersham) for Bcl-2 or HRP-linked anti-rabbit Ig (1:300 dilution; Amersham) for Bax. The immunoblots were developed using ECL western blotting reagents (Amersham) and the chemiluminescence was visualized and quantified using a Lumino image analyzer (LAS1000, Fuji Film, Tokyo).

**Immunofluorescence** Cells (1×10⁴/chamber) were preincubated in the complete medium on an 8-chamber slide (Nunc, Naperville, IL) for 48 h to allow them to grow exponentially and were fixed with 3% paraformaldehyde for 15 min at room temperature and with 70% methanol for 5 min at −20°C. The fixed cells were washed with PBS containing 0.1% bovine serum albumin and 0.05% Tween 20 (PBT) and were incubated with 1% rabbit serum or 1% swine serum for 30 min at room temperature to block the non-specific binding of antibodies. Then, the cells were exposed to anti-human Bcl-2 mAb (1:40 dilution) or anti-human Bax pAb (1:1000 dilution) at 4°C overnight. They were washed with PBT, then exposed further to fluorescein isothiocyanate (FITC)-conjugated rabbit anti-mouse Ig for Bcl-2 (1:30 dilution; Dako, Glostrup, Denmark) or FITC-conjugated swine anti-rabbit Ig for Bax (1:30 dilution; Dako) for 30 min at room temperature in the dark. Control cells were stained only with FITC-labeled second Ab. Finally, double-stranded DNA was stained with 100 ng/ml propidium iodide for 20 min at room temperature in the dark. The samples were observed using a confocal laser-scanning microscope (MRC-1024, Bio-Rad Microscience Division, Watford, UK) equipped with a computer (NEC, Tokyo).

**DNA extraction** After removal of the medium, the cells were washed once with ice-cold PBS. DNA was extracted from the cells (4×10⁶ cells/tube) using a Puregene DNA isolation kit (Genta System, Minneapolis, MN), according to the manufacturer’s instructions.

**Bax gene amplification by PCR (polymerase chain reaction)** Six exons of the bax gene were amplified using a PCR reagent system kit (GIBCO BRL, Life Technologies, Tokyo) and appropriate nucleotide primers under the reaction conditions in Table I, as described by Chou et al.,26 with a minor modification. Namely, PCR was performed in 100 μl mixtures containing PCR buffer [200 mM Tris-HCl (pH 8.4), 500 mM KCl, and 15 mM MgCl₂], 0.2 mM of each dNTP, 0.5 μM of each primer, 200 ng of DNA, and 2.5 U of Taq DNA polymerase. Thirty-five cycles of denaturation at 94°C for 1 min, annealing for 2 min either at 54°C for exon 1, at 58°C for exons 2–3 and
Expression levels of Bcl-2 and Bax protein in lung cancer cell lines We measured the expression levels of anti-apoptotic Bcl-2 protein and pro-apoptotic Bax protein because the Bax/Bcl-2 ratio is a very important factor to determine if the cell will survive or die.\(^{4,21}\) Levels of Bcl-2 varied relatively widely (0.2 to 1.9 arbitrary unit) among cell lines as compared with Bax levels (0.1 to 1.4 arbitrary unit) (Fig. 1). Peripheral lymphocytes expressed a little Bax and abundant Bcl-2, while immortalized lung cancer cells expressed Bax at five- to thirteen-fold higher levels than normal lymphocytes. NPC-1 and NPC-5 cells expressed large amounts of both Bcl-2 and Bax. The PC-3 cells, however, expressed only a little Bcl-2, in spite of a relatively high expression of Bax, which resulted in a high Bax/Bcl-2 ratio (3.9–7.9 times) compared with the ratios of other cell lines.

Intracellular Bcl-2 and Bax localizations Intracellular localizations of Bcl-2 and Bax were examined in lung cancer cells using a confocal laser-scanning microscope (Table II). Bcl-2 was localized in the cytoplasm in all cell lines (Fig. 2, a, b, c, d). However, Bax was localized in the nucleus and/or the cytoplasm (Fig. 2, e, f, g, h): (i) localized only in the cytoplasm in PC-10 and QG-56 squamous cell carcinomas and NPC-8 adenocarcinoma; (ii) localized only in the nucleus in PC-3 adenocarcinoma and NPC-1 and NPC-5 small cell carcinomas; (iii) localized either in the nucleus or the cytoplasm (Fig. 2, a, b, c, d). However, Bax was localized in the nucleus and/or the cytoplasm (Fig. 2, e, f, g, h): (i) localized only in the cytoplasm in PC-10 and QG-56 squamous cell carcinomas and NPC-8 adenocarcinoma; (ii) localized only in the nucleus in PC-3 adenocarcinoma and NPC-1 and NPC-5 small cell carcinomas; (iii) localized either in the nucleus or the cytoplasm in NPC-2 squamous cell carcinoma, NPC-4 adenocarcinoma and PC-6 small cell carcinoma; and (iv) localized in both the nucleus and the cytoplasm in NPC-5 squamous cell carcinoma. Thus, the cytoplasmic and/or nuclear localization of Bax was unrelated to histologic cell type.

**Bax gene amplification** Bax consists of 192 amino acid residues and has BH1, BH2, and BH3 domains and a transmembrane segment at the C-terminus (Fig. 3a). Genomic DNAs of ten lung cancer cell lines were screened for mutation in the bax gene by PCR and a direct sequencing strategy. The amplicon sizes of the PCR products of exons 1, 2–3, 4, 5, and 6 were 207, 400, 209, 192, and 237 bp, respectively (Table I, Fig. 3b).

**BH3 domain sequencing** The third exon of bax con-

---

Table I. Sequences of Oligonucleotide Primers and Conditions Used in PCR Amplification of Bax Gene

| Primers | Sequence | \(T_a\) (°C) | bp |
|---------|----------|----------|-----|
| bax exon 1 | Sense 5'-CGTTCAGCGGGCTCTCA-3' | 54 | 207 |
| | Antisense 5'-CAGGCCCTAAGGATCC-3' | | |
| bax exon 2, 3 | Sense 5'-CCCCCTAGAACCAGACTC-3' | 58 | 400 |
| | Antisense 5'-GGCGTGAGCCTTGTGCT-3' | | |
| bax exon 4 | Sense 5'-TCCCCAGTGTCACAGAT-3' | 58 | 209 |
| | Antisense 5'-TCCTCCTGCAGGATTGC-3' | | |
| bax exon 5 | Sense 5'-CAGGCAGTGAGGCAAGGT-3' | 62.5 | 192 |
| | Antisense 5'-GCAGTGGGAGGTTGAGGAG-3' | | |
| bax exon 6 | Sense 5'-CCCCCTGGCCGAGTCGACTGGA-3' | 60 | 237 |
| | Antisense 5'-AATGCCATGTCCCCAAAT-3' | | |

\(a\) 5% dimethyl sulfoxide was added.

\(b\) Optimum annealing temperature.

\(c\) Amplicon size expected, in base pairs (bp).
tained the BH3 domain spanning the codons 59–73, which is necessary for homodimerization, heterodimerization and proapoptotic activity.4) Also, exon 3 contains a stretch of eight consecutive deoxyguanosine residues, the poly (G)8 tract ATG GGG GGG G at codons 38–41 relative to the ATG start codon, which was proposed as a potential site for heterozygous frameshift mutation involving a single nucleotide deletion or insertion (Table III).28–35) Sequencing analysis of exon 3 after PCR amplification with the sense and antisense primers showed no mutation in the BH3 domain or the poly (G)8 tract (data not shown).

Transmembrane domain sequencing We focused on the C-terminal coding region of the bax gene because Bax

![Diagram](image1.png)

**Fig. 1.** Bcl-2 and Bax expression levels in human lung cancer cell lines. a) Cell lysates containing 100 µg/ml total protein were subjected to SDS-PAGE followed by western blotting using anti-human Bcl-2 mAb and anti-human Bax pAb. b) The levels of Bcl-2 (■) and Bax (▲) in western blot bands were measured using a densitometer and the Bax/Bcl-2 ratio (○) was calculated. Data are mean values ± SD of three independent experiments.

**Table II.** Distribution of Bcl-2 and Bax Proteins in Human Lung Cancer Cell Lines

| Cell line | Bcl-2 localization | Bax localization | Histologic cell type |
|-----------|--------------------|-----------------|---------------------|
| NPC-8     | C                  | C               | Ad                  |
| PC-10     | C                  | C               | Sq                  |
| QG-56     | C                  | C               | Sq                  |
| NPC-1     | C                  | N               | SCC                 |
| PC-3      | C                  | N               | Ad                  |
| QG-90     | C                  | N               | SCC                 |
| NPC-2     | C                  | N or C          | Sq                  |
| NPC-4     | C                  | N or C          | Ad                  |
| PC-6      | C                  | N or C          | SCC                 |
| NPC-5     | C                  | N and C         | Sq                  |

*a) C, cytoplasm; N, nucleus.
*b) Ad, adenocarcinoma; Sq, squamous cell carcinoma; SCC, small cell carcinoma.

![Diagram](image2.png)

**Fig. 2.** Bcl-2 and Bax intracellular localizations. Cells were fixed and Bcl-2 (left) and Bax (right) were stained as described in “Materials and Methods.” Images represent Bcl-2 cytoplasmic localization in a) PC-10, b) PC-3, c) NPC-4, and d) NPC-5 cells. Green fluorescence and red fluorescence are specific for Bcl-2 and DNA, respectively. Bax localizations are different among the cell lines; Bax is localized in e) the cytoplasm of PC-10; f) the nucleus of PC-3; g) the nucleus or the cytoplasm of NPC-4; and h) both the nucleus and the cytoplasm of NPC-5. The green fluorescence is Bax and red fluorescence is DNA, while the overlap of green and red fluorescence gives the yellow color.
protein, at its extreme C-terminus, contains a single trans-
membrane segment that functions in anchoring Bax into
organelle membranes.7) We initially considered that exon 6
of bax containing the transmembrane domain at codon
172–192 might be frequently mutated in lung cancer cell
lines. Therefore, the PCR products of exon 6 were
sequenced using the sense primer of exon 6. A silent point
mutation in codon 184 (TCG→TCA) was found (Fig. 4a)
in all cell lines tested. The two codons code for the same
amino acid, serine. To confirm this silent point mutation,
the PCR products were sequenced using the antisense
primer of exon 6, and we found that the nucleotide
sequence at codon 184 was changed from AGC to AGT
(Fig. 4b).

**Mutation analysis of the entire bax sequence** Bax lacks
the NLS in the primary structure,21) and we confirmed that
Bax had no NLS using PSORT II software (Institute of
Molecular Biology, Osaka University). While the NLS
had not been identified within the primary structure of
Bax, we found that Bax was localized in the nucleus in 7
of 10 cell lines. To determine if bax newly expresses an

---

**Table III. Summary of Bax Frameshift Mutations (%) at the
(G)8 Tract in Tumors**

| Tumorsa) | Mutations (%) | Referenceb) |
|----------|--------------|--------------|
| MMP* colorectal | 51 | 28 | |
| MI* gastric | 33 | 29 | |
| MI* endometrial | 12 | 29 | |
| MI* colorectal | 41 | 29 | |
| MMP* gastric | 64 | 30 | |
| MI* gastric carcinomas | 67 | 31 | |
| HNPCC adenocarcinomas | 54.5 | 32 | |
| HNPCC adenomas | 15.4 | 32 | |
| MMP* HNPCC | 52 | 33 | |
| Hematopoietic malignancy | 21 | 34 | |
| DG75 and Jurkat cells of human hematopoietic malignancies | recorded in both | 35 | |

**Footnotes:**

a) MMP*, tumor with microsatellite mutator phenotype; MI*, tumor with microsatellite instability; HNPCC, hereditary non-polyposis colorectal cancer.
b) Reference number (see reference list).
NLS resulting from several mutations in the gene encoding Bax, we examined whole \textit{bax} sequence in 10 cell lines, but we found neither mutation in these sequences nor expression of a new NLS.

**DISCUSSION**

Apoptosis-inducing proteins are normally coexpressed with antiapoptotic proteins, and the relative ratios between antiapoptotic (e.g. Bcl-2) and proapoptotic proteins (e.g. Bax) determine whether the cell will survive or die.\textsuperscript{4, 21}) Previous studies indicated that, in many cancers, expression levels of Bcl-2 increase, while Bax protein levels decrease.\textsuperscript{36–40}) Our data show that immortalized lung cancer cells express Bax at five- to thirteen-fold higher levels than normal lymphocytes. As the Bax expression itself, at least at physiological levels, is not lethal to cells,\textsuperscript{12}) our results support recent observations that a high expression of Bax without any apoptotic stimulus does not induce apoptosis.\textsuperscript{21, 41}) For example, sympathetic neurons expressing high levels of Bax mRNA will not undergo apoptosis unless deprived of growth factors.\textsuperscript{41}) Even cells stably over-expressing Bax proliferate normally, and Bax only accelerates cell death after receiving an external signal, such as interleukin-3 withdrawal.\textsuperscript{21}) Therefore, the lung cancer cell lines may proliferate normally and survive even if they contain Bax at a high Bax/Bcl-2 ratio compared with normal lymphocytes.

In this study we found a normal localization of Bcl-2 in lung cancer cell lines, which is consistent with the cytosolic localization in other studies.\textsuperscript{9, 42}) Conversely, Bax had abnormal nuclear localization in seven cell lines: NPC-1, NPC-2, PC-3, NPC-4, NPC-5, PC-6, and QG-90. The nuclear localization of Bax may endow cancer cells with resistance to apoptosis and afford a growth advantage to these cell lines. Our question was, might the nuclear localization of Bax be due to a mutation in the BH-3 domain? Mutant Bax missing its BH3 domain fails to dimerize with Bcl-XL or Bax.\textsuperscript{43, 44}) Other \textit{bax} mutations, such as single amino acid substitutions within the BH3 domain, result in a decrease in the ability of Bax to dimerize.\textsuperscript{50}) To test the possibility that lung cancer cells have a mutation in the BH3 domain of Bax resulting in intracellular Bax localization by disrupting the association between Bax and Bcl-2 in lung cancer cell lines, we analyzed the nucleotide sequence of the BH3 domain; however, we found no mutation. Frequent frameshift mutations of \textit{bax} in simple repeated sequences within the coding region exist in some cell lines and gastrointestinal cancer, as shown in Table III.\textsuperscript{28–35}) Therefore, we examined \textit{bax} mutations at the repetitive sequences within its coding region. Two regions of the gene, poly (G)\textsubscript{8} and poly (C)\textsubscript{6} tracts, were analyzed. No mutation was observed in either tract in any of the cell lines. Frameshift mutation should result in the production of a truncated Bax protein.\textsuperscript{29}) The absence of Bax expression in some cell lines of human hemopoietic malignancies\textsuperscript{35} and colorectal cancers\textsuperscript{28, 32}) is due to insertion or deletion of a single residue in the (G)\textsubscript{8} tract within the \textit{bax} coding sequence. This alters the reading frame and results in premature termination of Bax translation. In human lung cancer cell lines, we easily detect Bax as a 21-kDa single band in all cell lines by western blotting using the antibody that recognizes the epitope from amino acid 43 to amino acid 61, just after the (G)\textsubscript{8} tract, which also proved that this area of \textit{bax} had no frameshift mutation.

| Tumors \textsuperscript{a)} | Exon | Domain | Nucleotide | Codon | bp alteration | Amino acid alteration |
|-----------------------------|------|--------|------------|-------|--------------|----------------------|
| Gastrointestinal\textsuperscript{33}) | 6 | 506 | 169 | ACG to ATG | Thr to Met |
| Gastric\textsuperscript{30}) | 2 | 84–86 | 29 | GGG to GGGG | frameshift |
| Colorectal\textsuperscript{30}) | 3 BH3 | 174 | 58 | AAG to AAA | Lys to Asn |
| Colorectal\textsuperscript{30}) | 3 BH3 | 203 | 68 | GAC to GTC | Asp to Val |
| Colorectal\textsuperscript{30}) | 4 | 266–267 | 89 | CGA to CGTA | frameshift |
| Colorectal\textsuperscript{30}) | 4 | 276 | 92 | TTT to TTA | Phe to Leu |
| Gastric\textsuperscript{30}) | 5 BH2 | 453 | 151 | TGG to TGA | Trp to stop codon |
| Gastric\textsuperscript{30}) | 6 BH2 | 495 | 165 | TTT to TTA | Phe to Leu |
| Gastric\textsuperscript{30}) | 6 | 505 | 169 | ACG to GCG | Thr to Ala |
| Colorectal\textsuperscript{30}) | 6 | 505 | 169 | ACG to GCG | Thr to Ala |
| Colorectal\textsuperscript{30}) | 6 | 506 | 169 | ACG to ATG | Thr to Met |
| Colon\textsuperscript{30}) | 6 | 506 | 169 | ACG to ATG | Thr to Met |
| Hematopoietic\textsuperscript{49}) | 3 | 199 | 67 | GGG to AGG | Gly to Arg |
| Hematopoietic\textsuperscript{49}) | 4 BH1 | 323 | 108 | GGC to GTC | Gly to Val |
| Hematopoietic\textsuperscript{49}) | intron 5 | 508 | in Bax\textsubscript{β} | CGT to TGT | Arg to Cys |

\textsuperscript{a)} Reference number (see reference list).
Another essential region of Bax is the C-terminal hydrophobic segment spanning the last 21 amino acids of exon 6. The C-terminal sequence consists of a hydrophobic α-helix to be inserted into host membranes.\textsuperscript{13} Deletion of the C-terminal eliminates the ability of Bax to associate with organelles and inhibits the Bax redistribution during apoptosis.\textsuperscript{13} The amino acid serine at codon 184 (Ser184) is most important in regulating Bax subcellular localization, and mutation of Ser184 causes Bax to remain in either of two subcellular sites, the cytosol or the mitochondria, depending on the amino acid substitution.\textsuperscript{14} Therefore, we speculated that a mutation in the transmembrane segment might disturb the intracellular Bax localization in lung cancer cell lines. We found a silent point mutation in codon 184 in all cell lines, but this mutation has no effect on the amino acid sequence because the two codons are both translated into serine. As Bax had a normal transmembrane segment in all cell lines, but showed various intracellular localizations, we concluded that the C-terminal domain might not determine Bax nuclear localization.

The selectivity of nuclear transport resides in nuclear import signals, which only nuclear proteins contain.\textsuperscript{45} A typical signal peptide sequence for the nuclear import signal is -Pro-Pro-Lys+ -Lys+ sequence.\textsuperscript{45} This sequence consists of four to eight amino acid residues that are rich in positively charged amino acids, such as lysine and arginine and usually contains proline. A mutation in a single amino acid (Lys+ to Thr) prevents nuclear transport and causes the mutant protein to remain in the cytoplasm.\textsuperscript{46} Theoretically, the active nuclear transport of protein is thought to be mediated by the NLS and cognate transport factors.\textsuperscript{47} Therefore, binding of Bax protein to nuclear pore complexes may be necessary for Bax to translocate into the nucleus. But Bax lacks the NLS in the primary structure.\textsuperscript{31} So, we examined whether Bax may newly express the NLS resulting from accumulation of several mutations in the gene encoding Bax, but found no mutation creating a new NLS in the whole bax sequence. However, because projects to discover new monopartite or bipartite NLSs are in progress,\textsuperscript{47} the possibility that Bax may have an undiscovered NLS can not be ruled out. Phosphorylation influences both localization and the activity of the apoptosis promoter Bad,\textsuperscript{50} and phosphorylation of Bcl-2 may regulate its function.\textsuperscript{49} Although Ser184 appears important in the control of Bax localization and toxicity, no phosphorylation of Bax has been found before or after cell death.\textsuperscript{14} Because we detected only a single band of Bax protein at 21 kDa, we considered that Bax was neither phosphorylated nor dephosphorylated, and that the nuclear localization of Bax did not depend on the phosphorylation pathway.

The mutations of the bax gene, as listed in Tables III and IV, may have an important role in the multistep pathogenesis of hematological malignancies,\textsuperscript{34, 35, 49} the genesis of endometrial, gastric, and colorectal cancers with microsatellite instability,\textsuperscript{29} human adenocarcinomas with microsatellite mutator phenotype,\textsuperscript{29} and adenoma-carcinoma transition in hereditary non-polyposis colorectal cancer (HNPPC) tumorigenesis,\textsuperscript{12, 33} because mutant Bax lacks its function as a promoter of apoptosis in these cancers. The above studies showed that the disruption of the bax gene may be an important cause of carcinogenesis in a variety of cancers. However, Japanese HNPPC patients having microsatellite instability,\textsuperscript{29} and pancreatic cancer patients with a high incidence of microsatellite instability\textsuperscript{29} showed no mutation in the bax gene. Our results are consistent with these findings. Possible explanations for these findings are that the bax mutation may not have an important role in the development of lung cancer and that a transporter of Bax to the nucleus, which has stronger affinity for Bax than Bcl-2 and mitochondrial membrane, may exist.

We found that all the cell lines examined expressed high levels of wild-type Bax protein and that the transmembrane domain of Bax had no role in determining the nuclear Bax localization in established lung cancer cell lines. Therefore, we conclude that the nuclear localization of Bax may be induced by a mechanism other than bax mutation, and further study is needed to clarify the native conformation of Bax in lung cancer cell lines and the possible post-translation modification of nucleus-associated Bax.

(Received June 23, 2000/Revised August 8, 2000/Accepted August 25, 2000)

REFERENCES
1) Farrow, S. N. and Brown, R. New members of the Bcl-2 family and their protein partners. \textit{Curr. Opin. Genet. Dev.}, \textbf{6}, 45–49 (1996).
2) Hanada, M., Aime-Sempe, C., Sato, T. and Reed, J. C. Structure-function analysis of Bcl-2 protein. Identification of conserved domains important for homodimerization with Bcl-2 and heterodimerization with Bax. \textit{J. Biol. Chem.}, \textbf{270}, 11962–11969 (1995).
3) Zha, H., Fisk, H. A., Yaffe, M. P., Mahajan, N., Herman, B., and Reed, J. C. Structure-function comparisons of the proapoptotic protein Bax in yeast and mammalian cells. \textit{Mol. Cell. Biol.}, \textbf{16}, 6494–6508 (1996).
4) Sedlak, T. W., Oltvai, Z. N., Yang, E., Wang, K., Boise, L. H., Thompson, C. B. and Korsmeyer, S. J. Multiple Bcl-2 family members demonstrate selective dimerizations with Bax. \textit{Proc. Natl. Acad. Sci. USA}, \textbf{92}, 7834–7838 (1995).
5) Chittenden, T., Harrington, E. A., O’Connor, R., Flemington, C., Lutz, R. J., Evan, G. I. and Guild, B. C.
Induction of apoptosis by the Bcl-2 homologue Bak. Nature, 374, 733–736 (1995).
6) Zha, J., Harada, H., Yang, E., Jockel, J. and Korsmeyer, S. J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 not Bcl-X. Cell, 87, 619–628 (1996).
7) Nguyen, M., Millar, D. G., Yong, V. W., Korsmeyer, S. J. and Shore, G. C. Targeting of Bcl-2 to the mitochondrial outer membrane by a COOH-terminal signal anchor sequence. J. Biol. Chem., 268, 25265–25268 (1993).
8) Han, J., Sabbatini, P., Perez, D., Rao, L., Modha, D. and White, E. The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. Genes Dev., 10, 461–477 (1996).
9) Krajewski, S., Krajewska, M., Shabaik, A., Miyashita, T., Wang, H. G. and Reed, J. C. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am. J. Pathol., 145, 1323–1336 (1994).
10) Huang, Y. T., Wolter, K. G. and Youle, R. J. Cytosol-to-membrane redistribution of Bax and Bcl-XL during apoptosis. Proc. Natl. Acad. Sci. USA, 94, 3668–3672 (1997).
11) Shibasaka, F., Kondo, E., Akagi, T. and McKeon, F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature, 386, 728–731 (1997).
12) Wolter, K. G., Huang, Y.-T., Smith, C. L., Nechushtan, A., Xi, X.-G. and Youle, R. J. Movement of Bax from the cytosol to mitochondria during apoptosis. J. Cell Biol., 139, 1281–1292 (1997).
13) Mandal, M., Adam, L., Mendelsohn, J. and Kumar, R. Nuclear targeting of Bax during apoptosis in human colorectal cancer cells. Oncogene, 17, 999–1007 (1998).
14) Nechushtan, A., Smith, C. L., Huang, Y.-T. and Youle, R. J. Conformation of the Bax C-terminus regulates subcellular localization and cell death. EMBO J., 18, 2330–2341 (1999).
15) Priault, M., Camougrand, N., Chaudhuri, B. and Manon, S. Role of the C-terminal domain of Bax and Bcl-XL in their localization and function in yeast cells. FEBS Lett., 443, 225–228 (1999).
16) Goping, I. S., Gross, A., Lavoie, J. N., Nguyen, M., Lemmerson, R., Roth, K., Korsmeyer, S. J. and Shore, G. C. Regulated targeting of BAX to mitochondria. J. Cell Biol., 143, 207–215 (1998).
17) Gross, A., Jockel, J., Wei, M. C. and Korsmeyer, S. J. Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J., 17, 3878–3885 (1998).
18) Nishita, M., Inoue, S., Tsuda, M., Tateda, C. and Miyashita, T. Nuclear translocation and increased expression of Bax and disturbance in cell cycle progression without prominent apoptosis induced by hyperthermia. Exp. Cell Res., 244, 357–366 (1998).
19) Thielmann, H. W., Popanda, O. and Staab, H. J. Subnuclear distribution of DNA topoisomerase I and Bax protein in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan. J. Cancer Res. Clin. Oncol., 125, 193–208 (1999).
20) Lopez, E., Pozas, E., Rivera, R. and Ferrer, I. Bcl-2, Bax and Bcl-x expression following kainic acid administration at convulsant doses in the rat. Neuroscience, 91, 1461–1470 (1999).
21) Oltvai, Z. N., Milliman, C. L. and Korsmeyer, S. J. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programme cell death. Cell, 74, 609–619 (1993).
22) Apte, S. S., Mattei, M. G. and Olsen, B. R. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX delta. Genomics, 26, 592–594 (1995).
23) Zhou, M., Demo, S. D., McClure, T. N., Crea, R. and Bitler, C. M. A novel splice variant of the cell death-promoting protein BAX. J. Biol. Chem., 273, 11930–11936 (1998).
24) Shih, B., Triebe, D., Kajiji, S., Iwata, K. K., Bruskin, A. and Mahajna, J. Identification and characterization of a novel bax variant missing the BH2 and the transmembrane domains. Biochem. Biophys. Res. Commun., 254, 779–785 (1999).
25) Inoue, S., Takaoka, K., Endo, T., Mizuno, S., Ogawa, Y., Yoshiida, M. and Ohnuma, T. In vitro confirmation of newly established lung cancer cell lines using flow cytometry and multicellular tumor spheroids. Lung Cancer, 17, 85–101 (1997).
26) Chou, D., Miyashita, T., Mohrenweiser, H. W., Ueki, K., Kastury, K., Druck, T., von Deimling, A., Huebner, K., Reed, J. C. and Louis, D. N. The BAX gene maps to the glioma candidate region at 19q13.3, but is not altered in human gliomas. Cancer Genet. Cytogenet., 88, 136–140 (1996).
27) Sambrook, J., Fritsch, E. F. and Maniatis, T. “Molecular Cloning: A Laboratory Manual,” pp. 630–631 (1989). Cold Spring Harbor Laboratory Press, New York.
28) Rampino, N., Yamamoto, H., Ionov, Y., Li, Y., Sawai, H., Reed, J. C. and Perou, M. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science, 275, 967–969 (1997).
29) Ouyang, H., Furukawa, T., Ake, T., Kato, Y. and Horii, A. The BAX gene, the promoter of apoptosis, is mutated in genetically unstable cancers of the colorectum, stomach, and endometrium. Clin. Cancer Res., 4, 1071–1074 (1998).
30) Yamamoto, H., Sawai, H. and Perou, M. Frameshift somatic mutations in gastrointestinal cancer of the microsatellite mutator phenotype. Cancer Res., 57, 4420–4426 (1997).
31) Chung, Y. J., Park, S. W., Song, J. M., Lee, K. Y., Seo, E. J., Choi, S. W. and Rhyu, M. G. Evidence of genetic progression in human gastric carcinomas with microsatellite instability. Oncogene, 15, 1719–1726 (1997).
32) Yagi, O. K., Akiyama, Y., Nomizu, T., Iwama, T., Endo, M. and Yuasa, Y. Proapoptotic gene BAX is frequently mutated in normal and xeroderma pigmentosum fibroblasts after irradiation with UV light and gamma rays or treatment with topotecan. J. Cancer Res. Clin. Oncol., 125, 193–208 (1999).
mutated in hereditary nonpolyposis colorectal cancers but not in adenomas. *Gastroenterology*, **114**, 268–274 (1998).
33) Yamamoto, H., Sawai, H., Weber, T. K., Rodriguez-Bigas, M. A. and Peruch, M. Somatic frameshift mutations in DNA mismatch repair and proapoptosis genes in hereditary nonpolyposis colorectal cancer. *Cancer Res.*, **58**, 997–1003 (1998).
34) Meijerink, J. P., Mensink, E. I., Wang, K., Sedlak, T. W., Sloetjes, A. W., de Witte, T., Waksman, G. and Korsmeyer, S. J. Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. *Blood*, **91**, 2991–2997 (1998).
35) Brimmell, M., Mendiola, R., Mangion, J. and Packham, G. BAX frameshift mutations in cell lines derived from human haemopoietic malignancies are associated with resistance to apoptosis and microsatellite instability. *Oncogene*, **16**, 1803–1812 (1998).
36) Reed, J. C., Kitada, S., Takayama, S. and Miyashita, T. Regulation of chemoresistance by the bcl-2 oncogene in non Hodgkin’s lymphoma and lymphocytic leukemia cell lines. *Ann. Oncol.*, **5**, 61–65 (1994).
37) Yang, E. and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the Bcl-2 family and cell death. *Blood*, **88**, 386–401 (1996).
38) Bargou, R. C., Daniel, P. T., Mapara, M. Y., Bommert, K., Wagener, C., Kallinich, B., Royer, H. D. and Dorken, B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. *Int. J. Cancer*, **60**, 854–859 (1995).
39) Agualar-Santelises, M., Rottenberg, M. E., Lewin, N., Mellstedt, H. and Jondal, M. Bcl-2, Bax and p53 expression in B-CLL in relation to *in vitro* survival and clinical progression. *Int. J. Cancer*, **69**, 114–119 (1996).
40) Gazzaniga, P., Gradilone, A., Vercillo, R., Gandini, O., Silvestri, I., Napolitano, M., Alboni, L., Vincenzoni, A., Gallucci, M., Frati, L. and Agliano, A. M. Bcl-2/bax mRNA expression ratio as prognostic factor in low-grade urinary bladder cancer. *Int. J. Cancer*, **69**, 100–104 (1996).
41) Deckwerth, T. L., Elliott, J. L., Knudson, C. M., Johnson, E. M., Jr., Snider, W. D. and Korsmeyer, S. J. BAX is required for neuronal death after trophic factor deprivation and during development. *Neuron*, **17**, 401–411 (1996).